GeneCradle Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 9

GeneCradle General Information

Description

Developer of gene therapy drugs intended to treat rare diseases. The company's drugs are mediated by recombinant adeno-associated virus vector (rAAV) delivery technology to create new drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases, hereditary diseases, and ophthalmic diseases, providing healthcare professionals with a product production guarantee that meets good manufacturing practices (GMP) requirements for the development of multi-variety and multi-field genetic medicines.

Contact Information

Website
www.bj-genecradle.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 2, Deshang Science and Technology Park
  • No. 35, Jinghai 3rd Road
  • Beijing, 100176
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Building 2, Deshang Science and Technology Park
  • No. 35, Jinghai 3rd Road
  • Beijing, 100176
  • China
+86 010

GeneCradle Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GeneCradle Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 19-Feb-2025 Completed Clinical Trials - General
5. Early Stage VC 03-Aug-2023 Completed Clinical Trials - General
4. Early Stage VC 16-Jun-2023 Completed Clinical Trials - General
3. Early Stage VC (Series A) 08-Feb-2022 Completed Clinical Trials - General
2. Early Stage VC 25-Feb-2021 $15.5M $15.5M Completed Clinical Trials - General
1. Early Stage VC 31-Jul-2020 Completed Pre-Clinical Trials
To view GeneCradle’s complete valuation and funding history, request access »

GeneCradle Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
CASH Capital Venture Capital Minority
Gandao Investment Holding Company Asset Manager Minority
Huajin Investment Venture Capital Minority
Shenzhen Capital Group Venture Capital Minority
Yizhuang Guotou Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

GeneCradle Acquisitions (1)

GeneCradle’s most recent deal was a Merger/Acquisition with FivePlus Gene. The deal was made on 15-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
FivePlus Gene 15-Jun-2023 Merger/Acquisition Pharmaceuticals
To view GeneCradle’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

GeneCradle Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
FivePlus Gene Beijing, China 2018

GeneCradle FAQs

  • When was GeneCradle founded?

    GeneCradle was founded in 2018.

  • Where is GeneCradle headquartered?

    GeneCradle is headquartered in Beijing, China.

  • What industry is GeneCradle in?

    GeneCradle’s primary industry is Drug Discovery.

  • Is GeneCradle a private or public company?

    GeneCradle is a Private company.

  • What is GeneCradle’s current revenue?

    The current revenue for GeneCradle is .

  • How much funding has GeneCradle raised over time?

    GeneCradle has raised $61M.

  • Who are GeneCradle’s investors?

    CASH Capital, Gandao Investment Holding Company, Huajin Investment, Shenzhen Capital Group, and Yizhuang Guotou are 5 of 9 investors who have invested in GeneCradle.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process